Note : Les descriptions sont présentées dans la langue officielle dans laquelle elles ont été soumises.
CA 02357450 2001-09-19
A0000336-O 1D
PHENOXAZINE ANALOGS USEFUL AS AMYLOID AGGREGATION
INHIBITORS AND TREATMENT OF ALZHEIMER' S DISEASE AND
DISORDERS RELATED TO AMYLOIDOSIS
DM FILE/PD A0000336PCT
CA 02357450 2001-09-19
A0000336-O 1D
-1-
PHENOXAZINE ANALOGS USEFUL AS AMYL0117 AGGREGATION
INHIBITORS AND TREATMENT OF ALZHEIMER' S DISEASE AND
DISORDERS RELATED TO AMYLOIDOSIS
FIELD OF THE INVENTION
This invention relates to compounds useful for inhibiting amyloid protein
aggregation and imaging amyloid deposits. In addition, this invention relates
to a
method of treating Alzheimer's disease and disorders related to amyloidosis.
SUMMARY OF THE RELATED ART
Amyloidosis is a condition characterized by the accumulation of various
insoluble, fibrillar proteins in the tissues of a patient. The fibrillar
proteins that
comprise the accumulations or deposits are called amyloid proteins. While the
particular proteins or peptides found in the deposits vary, the presence of
fibrillar
morphology and a large amount of (3-sheet secondary structure is common to
many types of amyloids. An amyloid deposit is formed by the aggregation of
amyloid proteins, followed by the further combination of aggregates and/or
amyloid proteins.
The presence of amyloid deposits has been shown in various diseases, each
with its particular associated protein, such as Mediterranean fever, Muckle-
Wells
syndrome, idiopathetic myeloma, amyloid polyneuropathy, amyloid
cardiomyopathy, systemic senile amyloidosis, hereditary cerebral hemorrhage
with amyloidosis, Alzheimer's disease, Down syndrome, scrapie, Creutzfeldt-
Jakob disease, kuru, Gerstmann-Straussler-Scheinker syndrome, medullary
carcinoma of the thyroid, isolated atrial amyloid, /32-microglobulin amyloid
in
dialysis patients, inclusion body myositis, X32-amyloid deposits in muscle
wasting
disease, sickle cell anemia, Parkinson's disease, and Islets of Langerhans
diabetes
type 2 insulinoma.
CA 02357450 2001-09-19
-2-
Alzheimer's disease is a degenerative brain disorder characterized
clinically by progressive loss of memory, cognition, reasoning, judgement, and
emotional stability that gradually leads to mental deterioration and
ultimately
death. Because Alzheimer's disease and related degenerative brain disorders
are a
major medical issue for an increasingly aging population, the need for new
treatments and methods for diagnosing the disorders are needed.
A simple, noninvasive method for detecting and quantitating amyloid
deposits in a patient has been eagerly sought. Presently, detection of amyloid
deposits involves histological analysis of biopsy or autopsy materials. Both
methods have major drawbacks. For example, an autopsy can only be used for a
postmortem diagnosis.
The direct imaging of amyloid deposits in vivo is difficult, as the deposits
have many of the same physical properties (i.e., density and water content) as
normal tissues. Attempts to image amyloid deposits directly using magnetic
resonance imaging (MRI) and computer-assisted tomography (CAT) have been
disappointing and have detected amyloid deposits only under certain favorable
conditions. In addition, e~'orts to label amyloid deposits with antibodies,
serum
amyloid P protein, or other probe molecules has provided some selectivity on
the
periphery of tissues, but has provided for poor imaging of tissue interiors.
Thus, it would be useful to have a noninvasive technique for imaging and
quantitating amyloid deposits in a patient. In addition, it would be useful to
have
compounds that inhibit the aggregation of amyloid proteins to form amyloid
deposits. An object of this invention is to provide new compounds that are
useful
to diagnose and treat diseases associated with amyloidosis.
SUMMARY OF THE INVENTION
The present invention provides compounds that are useful in a method of
inhibiting amyloid protein aggregation, the method comprising the
administration
of an effective amount of the compound to a subject, preferably mammalian, in
need thereof.
CA 02357450 2001-09-19
-3-
The present invention is directed to phenoxazine derivatives and their use
as inhibitors of amyloid protein aggregation. The compounds of the invention
are
those having the structure of Formula I
R3
O
2
,/ N \ R
R
R1
C02H
wherein
R1 is hydrogen, lower alkyl, or cycloalkyl;
R2 is hydrogen, lower alkyl, lower alkoxy, halogen, hydroxy, aryl, heteroaryl,
arylalkyl, heteroarylalkyl, arylalkoxy, heteroarylalkoxy, cyano, carboxy,
alkoxycarbonyl, carbamoyl, sulfamoyl, nitro, trifluoromethyl, amino, or
mono- or dialkylamino;
R3 and R4 independently are hydrogen, lower alkoxy, aryl, heteroaryl, halogen,
hydroxy, cyano, carboxy, alkoxycarbonyl, carbamoyl, sulfamoyl, nitro,
trifluoromethyl, amino, mono- or dialkylamino, or
lower alkyl or lower alkenyl unsubstituted or substituted with one, two, or
three groups independently selected from oxo, halogen, hydroxy,
carboxy, carbamoyl, amino, mono- or dialkylamino, or
aryl or heteroaryl optionally substituted independently with up to three
groups selected from halogen, lower alkyl, lower alkoxy, hydroxy,
carboxy, alkoxycarbonyl, cyano, nitro, trifluoromethyl, amino,
mono- or dialkylamino, carbamoyl, carboxyalkyl,
alkoxycarbonylalkyl, sulfamoyl, or carbonylamino, or
R3 and R4 together form a carbocyclic group containing from five to seven
members, up to two of which members are optionally heteroatoms selected
from oxygen and nitrogen, where the carbocyclic group is optionally
substituted with one or two groups selected from halogen, lower alkyl,
lower alkoxy, mono- or dialkylamino, aryl, arylalkyl, or a heterocyclic
group.
CA 02357450 2001-09-19
-4-
The instant invention includes pharmaceutical compositions of compounds
of Formula I and a method of treating Alzheimer's disease, the method
comprising administering to a patient having Alzheimer's disease a
therapeutically effective amount of a compound of Formula I. Also provided is
a
method for treating disorders related to amyloidosis, the method comprising
administering to a patient having disorders related to amyloidosis a
therapeutically
effective amount of a compound of Formula I.
In a further embodiment, radiolabeled compounds of Formula I are
provided, as well as a method for detecting and quantitating amyloid deposits
by
administering such radiolabeled compound to an animal and measuring the
localization thereof in tissues.
Also provided is a method of inhibiting the aggregation of amyloid
proteins to form amyloid deposits, the method comprising administering to a
patient in need of inhibition of the aggregation of amyloid protein an amyloid
protein aggregation inhibiting amount of a compound of Formula I.
In a further embodiment, radiolabeled compounds of Formula I are
provided, as well as a method for detecting and quantitating amyloid deposits
by
administering such radiolabeled compound to an animal and measuring the
localization there of in tissues.
DETAILED DESCRIPTION OF THE INVENTION
The novel compounds encompassed by the instant invention are those
described by the general Formula I set forth above, and the pharmaceutically
acceptable salts, esters, amides, and prodrugs thereof.
Preferred compounds of Formula I are those in which R1 is hydrogen;
R2 is hydrogen, nitro, or amino; R3 is hydrogen, hydroxy, trifluoromethyl,
halogen, or nitro; and R4 is halogen, aryl, or arylalkyl.
In addition to the compounds of Formula I, the invention encompasses
compounds of Formula II
CA 02357450 2001-09-19
-5-
R3
O
2
I ~ N ~ R II
R
H
C02H
wherein R2, R3, and R4 are as defined above for Formula I.
Preferred compounds of Formula II are those in which R2 is hydrogen,
nitro, or amino; R3 is hydrogen, hydroxy, trifluoromethyl, halogen, or nitro;
and
R4 is halogen, aryl, or arylalkyl.
In addition, the invention encompasses compounds of Formula III
R3
O
2
RS A / N \ R
- III
Rl CO H
2
R6
wherein:
R1, R2, and R3 are as defined above for Formula I;
RS and R6 are as defined above for RZ in Formula II; and
A is absent, or is
lower alkyl or lower alkenyl unsubstituted or substituted with one or two
groups independently selected from oxo, halogen, hydroxy, carboxy,
carbamoyl, amino, mono- or dialkylamino.
Preferred compounds of Formula III are those in which R1 is hydrogen;
R2 is hydrogen, nitro or, amino; R3 is hydrogen, hydroxy, trifluoromethyl,
halogen; or nitro; RS is hydrogen or halogen; and R6 is hydrogen or halogen.
In addition, the invention encompasses compounds of Formula IV:
RS
O
2
N \ R IV
R6 I
R1 C02H
CA 02357450 2001-09-19
-6-
wherein R1, R2, R5, and R6 are as defined above for Formula I.
Preferred compounds of Formula IV are those in which Rl is hydrogen;
R2 is hydrogen, nitro, or amino; RS is hydrogen, lower alkyl, hydroxy, or
halogen;
and R6 is hydrogen, lower alkyl, hydroxy, or halogen.
Another preferred group of compounds are those of Formula I wherein R1
is alkyl.
Except as expressly defined otherwise, the following definition of terms is
employed throughout this specification.
The terms "alkyl", "lower alkyl", or "(C 1-C6)-alkyl" mean a straight or
branched hydrocarbon having from 1 to 6 carbon atoms and includes, for
example,
methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl,
n-pentyl,
n-hexyl, and the like. The alkyl group can also be substituted with one or
more of
the substituents listed below for aryl.
By "alkoxy," "lower alkoxy," or "(C1-C6)-alkoxy" in the present
invention is meant straight or branched chain alkoxy groups having 1 to 6
carbon
atoms, such as, for example, methoxy, ethoxy, propoxy, isopropoxy, n-butoxy,
sec-butoxy, tent-butoxy, pentoxy, 2-pentyl, isopentoxy, neopentoxy, hexoxy,
2-hexoxy, 3-hexoxy, and 3-methylpentoxy.
The term "cycloalkyl" means a carbocyclic ring having from 3 to 7 carbon
atoms. Examples include cyclopropyl, cyclopentyl, and cycloheptyl. The rings
may be substituted with one or more of the substituents listed below for aryl.
Examples include 2-aminocyclobutyl.
The term "halogen" includes chlorine, fluorine, bromine, and iodine, and
their monovalent radicals.
The term "aryl" means an aromatic carbocyclic group having a single ring
(e.g., phenyl), multiple rings (e.g., biphenyl), or multiple condensed rings
in
which at least one is aromatic (e.g., 1,2,3,4-tetrahydronaphthyl, naphthyl,
anthryl,
or phenanthryl), unsubstituted or substituted by 1 to 3 substituents selected
from
alkyl, O-alkyl and S-alkyl, OH, SH, -CN, halogen, 1,3-dioxolanyl, CF3, N02,
NH2, NHCH3, N(CH3)2, NHCO-alkyl, -(CH2)mC02H, -(CH2)mC02-alkyl,
-(CH2)mS03H, -NH alkyl, -N(alkyl)2, -CH2)mP03H2, -(CH2)mP03(alkyl)2,
CA 02357450 2001-09-19
-7-
-(CH2)mS02NH2, and -(CH2)mS02NH-alkyl wherein alkyl is defined as above
and m is 0, 1, 2, or 3. A preferable aryl group of the present invention is
phenyl.
Typical substituted phenyl groups include 2-chlorophenyl, 3-methoxyphenyl,
4-aminophenyl, 3,5-dinitrophenyl, 2,6-dibromo-4-ethoxyphenyl, and 2-hydroxy-
3-cyano-5-trifluoromethylphenyl.
The term "aralkyl" or "arylalkyl" means an alkyl moiety (as defined
above) substituted with an aryl moiety (also as defined above).
By heteroaryl (aromatic heterocycle) in the present invention is meant~ne
or more aromatic ring systems of 5-, 6-, or 7-membered rings containing at
least
one and up to four heteroatoms selected from nitrogen, oxygen, or sulfur. Such
heteroaryl groups include, for example, thienyl, furanyl, thiazolyl,
imidazolyl,
(is)oxazolyl, pyridyl, pyrimidinyl, (iso)quinolinyl, naphthyridinyl,
benzimidazolyl, and benzoxazolyl. The heterocycle is unsubstituted or
substituted
by 1 to 3 substituents selected from alkyl, O-alkyl and S-alkyl, OH, SH, -CN,
halogen, 1,3-dioxolanyl, CF3, N02, NH2, NHCH3, N(CH3)2, NHCO-alkyl,
-(CH2)mC02H, -(CH2)mC02-alkyl, -(CH2)mS03H, -NH alkyl, -N(alkyl)2,
-CH2)mP03H2~ -(CH2)mP03(alkyl)2, -(CH2)mS02~2~ and -(CH2)mS02~-
alkyl wherein alkyl is defined as above and m is 0, 1, 2, or 3. A preferable
heteroaryl group of the present invention is 2-, 3- or 4-pyridine. Examples of
substituted heteroaryl groups include 2-chloropyridin-4-yl,
6-methoxynaphthyridin-2-yl, 6-trifluoromethylpyrimidin-2-yl, 5,6-
diethoxybenzimidazol-2-yl, and 4-chloro-5-nitro-7-acetamidobenzoxazol-2-yl.
The symbol "-" means a covalent bond.
The term "pharmaceutically acceptable salt, ester, amide, and prodrug" as
used herein refers to those carboxylate salts, amino acid addition salts,
esters,
amides, and prodrugs of the compounds of the present invention which are,
within
the scope of sound medical judgement, suitable for use in contact with the
tissues
of patients without undue toxicity, irritation, allergic response, and the
like,
commensurate with a reasonable benefit/risk ratio, and ei~'ective for their
intended
use, as well as the zwitterionic forms, where possible, of the compounds of
the
invention. The term "salts" refers to the relatively nontoxic, inorganic and
organic
acid addition salts of compounds of the present invention. These salts can be
CA 02357450 2001-09-19
-8-
prepared in situ during the final isolation and purification of the compounds
or by
separately reacting the purified compound in its free base form with a
suitable
organic or inorganic acid and isolating the salt thus formed. Representative
salts
include the hydrobromide, hydrochloride, sulfate, bisulfate, nitrate, acetate,
oxalate, valerate, oleate, palmitate, stearate, laureate, borate, benzoate,
lactate,
phosphate, tosylate, citrate, maleate, fumarate, succinate, tartrate,
naphthylate
mesylate, glucoheptonate, lactobionate and laurylsulphonate salts, and the
like.
These may include cations based on the alkali and alkaline earth metals, such
as
sodium, lithium, potassium, calcium, magnesium, and the like, as well as,
nontoxic ammonium, quaternary ammonium, and amine cations including, but not
limited to ammonium, tetramethylammonium, tetraethylammonium, methylamine,
dimethylamine, trimethylamine, triethylamine, ethylamine, and the like. (See,
for
example, Berge S.M., et al., Pharmaceutical Salts, J. Pharm. Sci., 1977;66:1-
19
which is incorporated herein by reference.)
1 S Examples of pharmaceutically acceptable, nontoxic esters of the
compounds of this invention include C1-C6 alkyl esters wherein the alkyl group
is
a straight or branched chain. Acceptable esters also include CS-C7 cycloalkyl
esters as well as arylalkyl esters such as, but not limited to benzyl. C1-C4
alkyl
esters are preferred. Esters of the compounds of the present invention may be
prepared according to conventional methods.
Examples of pharmaceutically acceptable, nontoxic amides of the
compounds of this invention include amides derived from ammonia, primary
C1-C6 alkyl amines and secondary C1-C6 dialkyl amines wherein the alkyl
groups are straight or branched chain. In the case of secondary amines, the
amine
may also be in the form of a 5- or 6-membered heterocycle containing one
nitrogen atom. Amides derived from ammonia, C1-C3 alkyl primary amides and
C 1-C2 dialkyl secondary amides are preferred. Amides of the compounds of the
invention may be prepared according to conventional methods.
The term "prodrug" refers to compounds that are rapidly transformed
in vivo to yield the parent compound of the above formulas, for example, by
hydrolysis in blood. A thorough discussion is provided in Higuchi T. and
Stella V., Pro-drugs as Novel Deliver~Systems, Vol. 14 of the A.C.S. Symposium
CA 02357450 2001-09-19
-9-
Series, and in Bioreversible Carriers in Drug Design, ed. Edward B. Roche,
American Pharmaceutical Association and Pergamon Press, 1987, both of which
are incorporated herein by reference.
All of the foregoing pharmaceutically acceptable salts, esters, amides, and
prodrugs are readily prepared and used by pharmaceutical scientists and
medical
personnel to whom this invention is directed. Such compounds are those that
are
pharmaceutically acceptable and can be administered to animals, including
humans, for the treatments and other uses described herein.
In addition, the compounds of the present invention can exist in unsolvated
as well as solvated forms with pharmaceutically acceptable solvents such as
water,
ethanol, and the like. In general, the solvated forms are considered
equivalent to
the unsolvated forms for the purposes of the present invention.
Certain of the compounds of the present invention possess one or more
chiral centers and each center may exist in the R or S configuration. The
present
invention includes all diastereomeric, enantiomeric, and epimeric forms as
well as
the appropriate mixtures thereof. Additionally, the compounds of the present
invention may exist as geometric isomers. The present invention includes all
cis,
trans, syn, anti, entgegen (E), and zusammen (Z) isomers as well as the
appropriate mixtures thereof.
Representative compounds of the invention are shown below in Table 1.
TABLE 1
O / ~ O / N02
i / \ I \ I / N \
I
H ~ H C02H
C02H
1 2
CA 02357450 2001-09-19
-1W
TABLE 1 (continued)
\ O / N02 \ O / O
/ \ I I / \
i N
H
C02H H Cp2H
cl ~ -
No °
C1 \ I ~ O r I Z C1 I \ / I ~ O / I N02
N ~ Cl~ ~N w
i
H
C02H 6 H C02H
H
Cl I ~ I ~ O / I N02 Cl I ~ I ~ O / I N02
C1~ ~ \ C1
i
H
C02H R H C02H
NH F
CI I ~ I ~ O , I 2 3 I \ \ O /
Cl / ~N \ Cl / ~ N
i i
H C02H H C02H
10
\ O / I / \ O /
\ / \ \ I / \
i
H
C02H H C02H
11 12
HO / I \ O / I C1 , \ O /
HO \ / \ \ ~ / \
C1
H
13 C02H H C02H
14
CA 02357450 2001-09-19
-11-
TABLE 1 (continued)
CI
I
O / I /
\
i
H
15 C02H 16 H C02H
O / I CI \ \ O /
/ ~ \ I / I / \ I
C1
H I
17 C02H H C02H
18
C1
I \ ~ / I
C1 CI ~ / \
.,
11 CI / H C02H
C02H
19 20
/ \ O I \ N02 O
I ~ I I /
\ / / /
H \ I H
CO H C02Na
2
21 22
02N ~ / O ~ C1 \ / O W
i ~ I I ~ ~1 I i ~ ~ ~ i
CO Et CH2CC13 C02CH20Ac
2
23 24
CA 02357450 2001-09-19
-12-
O ~ C1 / O
/S~ ~~ ( , Cl ~ ~ ~ ,
H
CH3 C02H C02H
25 26
O
EtOC ~ O ~ NHCH3
H2NCH2CH2 H
H3C,j~~CH3 CONH2 C02CH2CCI3
27 28
Representative compounds of the present invention, which are
encompassed by Formula I include, but are not limited to the compounds in
Table 1 and their pharmaceutically acceptable acid or base addition salts, the
esters, amides, or prodrugs thereof.
The invention compounds of Formula I are readily prepared from
commercially available reactants, utilizing synthetic methodologies well-known
and routinely used by those skilled in the art of synthetic organic chemistry.
While
the invention compounds can be prepared by any number of alternative
processes,
typical synthetic routes utilized to prepare illustrative invention compounds
are
presented in Schemes 1 to 4. In the Schemes, R2, R5, and R6 have the meanings
defined above for Formula I.
CA 02357450 2001-09-19
-13-
Scheme 1
RS
W OH 02N
_~ R2 1. NaOAc/H20, reflex
R6 / NH2 Cl / 2. NaOH/H20, reflex N02
C02H
R~
RS
O
NaOH/H20, reflex I ~ I ~ R2
R6 H
C02H
CA 02357450 2001-09-19
-14-
Scheme 2
5
R ~ reduc. RS ~gS RS
\ ~ ~\
/ CHO I ' / OH
/ Br
R R6 R6
RS NaHIvmS/THF
P(P~ \ -78°C
+ - OHC \ OH
/ P(I'h)3 Br _
R6 I /
N02
R5 RS
H2, Raney Ni/THF \
/ ~ OH ~ / OH
R ~ / R6 I /
N02 \~
2
1. NaOAc/H20, reflux RS
2. NaOH/H20, reflux
OzN \ R2
R2
Cl /
C02H C02H
CA 02357450 2001-09-19
-15-
Scheme 3
5 O
R OHC OH RS O OH
NaOMe/MeOH ~ ~ OH
--'
R6 N02 6 / ~.
R N02
R5 O OH 1. NaOAc/H20, reflex
H2, Raney Ni/THF ~ ~ OH 2. NaOH/H20, reflex
02N
R6 NH2 I / R2 _
C1
RS C02H
O ~ / R2
R6 v H
C02H
CA 02357450 2001-09-19
-16-
Scheme 4
5
R OHC OH R5 O OH
+ ( ~ NaOMe/MeOH ~ ~ OH
/
6 N02
R R6 N02
NaOH/EtOH RS O
Dilute H2S04 ~ / ~ OH Et3SiH/TFA
R6 N02
RS RS OH
OH OH
W
/ ~ /
R6 ~ N02 R6 N02
H2, Raney Ni/THF 1 H2, Raney Ni/THF
R5 R5 OH
~ OH OH
W/
6
02N R ~2 R6 NH2
R2 1. NaOAc/H20, reflux 02N
\ R2 1. NaOAc/H20, reflux
CI / 2. NaOH/H20, reflux
C02H Cl / 2. NaOH/H20, reflux
C02H
RS
w ~ O ~ RS H
/ ~ / ~ / R2 ~~ ~ O
R6 H I / I / ( / R2
C02H R6 H
C02H
CA 02357450 2001-09-19
-1'7-
Scheme 1 involves the coupling of a 3-aminonaphthalen-2-of with a
2-chloro-3-nitrobenzoic acid to form the corresponding secondary amine, which
is
subsequently cyclized under basic conditions to form the desired
benzo[b]phenoxazinecarboxylic acid.
According to Scheme 2, a benzaldehyde is reduced to the corresponding
benzyl alcohol (e.g., via a metal hydride) which is then converted to the
benzyl
bromide (e.g., N-bromosuccinimide). The benzyl bromide can be converted to the
phosphonium salt which in turn is converted to the corresponding ylide upon
treatment with a strong base, and the ylide is then treated with the desired
3-hydroxy-4-nitrobenzaldehyde to afford a 5-(2-phenylvinyl)-2-nitrophenol
(i.e., Wittig reaction). The 5-(2-phenylvinyl)-2-nitrophenol is reduced to the
2-amino-5-(2-phenylethyl)phenol which is subsequently coupled to a 2-chloro-
3-nitrobenzoic acid and cyclized to form the desired 7-(2-phenylethyl)-
phenoxazinecarboxylic acid.
Scheme 3 illustrates the formation of various 7-(3-oxo-3-phenylprop-
1-enyl)phenoxazinecarboxylic acids. Initially, an acetophenone is coupled with
a
3-hydroxy-4-nitrobenzaldehyde to afford the 3-hydroxy-3-(3-hydroxy-
4-nitrophenyl)-1-phenylpropan-1-one. This nitro compound is reduced to the
amine and the amine is coupled and cyclized (dehydration also results) as
above
for Scheme 2 to produce the '7-(3-oxo-3-phenylprop-1-enyl)-
phenoxazinecarboxylic acid.
Finally, Scheme 4 shows the dehydration of a 3-hydroxy-3-(3-hydroxy-
4-nitrophenyl)-1-phenylpropan-1-one to the enone, which is subsequently
reduced
to produce two products, the 2-nitro-5-(3-phenylpropyl)phenol and the
5-(3-hydroxy-3-phenylpropyl)-2-nitrophenol. Each compound can independently
be reduced to the amine and coupled and cyclized as above to afford the final
products 7-(3-phenylpropyl)phenoxazinecarboxylic acid and 7-(3-hydroxy-
3-phenylpropyl)phenoxazinecarboxylic acid, respectively.
The invention also includes radiolabeled compounds of Formula I that are
useful for detecting and quantitating amyloid protein deposits. Such
radiolabeled
compounds are synthesized by standard methods, for example, by using a
radiolabeled starting material in any of the foregoing schemes. Typical
starting
CA 02357450 2001-09-19
-18-
materials are those having a 13C, 19F~ 1 SN~ 11 C~ or other radioactive atom
as part
of the molecule.
In the first step of the present method of imaging amyloid deposits, a
labeled compound of Formula I is introduced into a tissue or a patient in a
detectable quantity. The compound is typically part of a pharmaceutical
composition and is administered to the tissue or the patient by methods well-
known to those skilled in the art.
Those skilled in the art are familiar with the various ways to detect labeled
compounds. For example, MRI, positron emission tomography (PET), or single
photon emission computed tomography (SPELT) can be used to detect
radiolabeled compounds. The label that is introduced into the compound will
depend on the detection method desired. For example, if PET is selected as a
detection method, the compound must possess a positron-emitting atom, such as
11C or lgF.
Another example of a suitable label in a compound of Formula I is an atom
such as 13C, 15N, or 19F which can be detected using MRI, which is also
sometimes called nuclear magnetic resonance (NMR). In addition, the labeled
compounds of Formula I may also be detected by MRI using paramagnetic
contrast agents.
Another example of detection is electron paramagnetic resonance (EPR).
In this case, EPR probes which are well-known in the art, such as nitroxides,
can
be used.
The imaging of amyloid deposits can also be carried out quantitatively so
that the amount of amyloid deposits can be determined.
In the methods of treating disorders related to amyloidosis according to the
present invention, disorders such as Alzheimer's disease, a compound of
Formula I can be administered either orally, rectally, parenterally
(intravenously,
intramuscularly, or subcutaneously), intracisternally, intravaginally,
intraperitoneally, intravesically, locally (powders, ointments, or drops), or
as a
buccal or nasal spray. The invention provides pharmaceutical compositions
comprising a compound of Formula I mixed with a carrier, diluent, or
excipient.
CA 02357450 2001-09-19
-19-
Compositions suitable for parenteral injection may comprise
physiologically acceptable sterile aqueous or nonaqueous solutions,
dispersions,
suspensions or emulsions, and sterile powders for reconstitution into sterile
injectable solutions or dispersions. Examples of suitable aqueous and
nonaqueous
S carriers, diluents, solvents, or vehicles include water, ethanol, polyols
(propyleneglycol, polyethyleneglycol, glycerol, and the like), suitable
mixtures
thereof, vegetable oils (such as olive oil), and injectable organic esters
such as
ethyl oleate. Proper fluidity can be maintained, for example, by the use of a
coating such as lecithin, by the maintenance of the required particle size in
the
case of dispersions and by the use of surfactants.
These compositions may also contain adjuvants such as preserving,
wetting, emulsifying, and dispensing agents. Prevention of the action of
microorganisms can be ensured by various antibacterial and antifungal agents,
for
example, parabens, chlorobutanol, phenol, sorbic acid, and the like. It may
also be
desirable to include isotonic agents, for example sugars, sodium chloride, and
the
like. Prolonged absorption of the injectable pharmaceutical form can be
brought
about by the use of agents delaying absorption, for example, aluminum
monostearate and gelatin.
Solid dosage forms for oral administration include capsules, tablets, pills,
powders, and granules. In such solid dosage forms, the active compound is
admixed with at least one inert customary excipient (or carrier) such as
sodium
citrate or dicalcium phosphate, or (a) fillers or extenders, as for example,
starches,
lactose, sucrose, glucose, mannitol, and silicic acid; (b) binders, as for
example,
carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidone, sucrose, and
acacia; (c) humectants, as for example, glycerol; (d) disintegrating agents,
as for
example, agar-agar, calcium carbonate, potato or tapioca starch, alginic acid,
certain complex silicates, and sodium carbonate; (e) solution retarders, as
for
example, para~n; (f) absorption accelerators, as for example, quaternary
ammonium compounds; (g) wetting agents, as for example, cetyl alcohol and
glycerol monostearate; (h) adsorbents, as for example, kaolin and bentonite;
and
(i) lubricants, as for example, talc, calcium stearate, magnesium stearate,
solid
polyethylene glycols, sodium lauryl sulfate, or mixtures thereof. In the case
of
capsules, tablets, and pills, the dosage forms may also comprise buffering
agents.
CA 02357450 2001-09-19
-20-
Solid compositions of a similar type may also be employed as fillers in
soft- and hard-filled gelatin capsules using such excipients as lactose or
milk
sugar, as well as high molecular weight polyethyleneglycols, and the like.
Solid dosage forms such as tablets, dragees, capsules, pills, and granules
can be prepared with coatings and shells, such as enteric coatings and others
well-
known in the art. They may contain opacifying agents, and can also be of such
composition that they release the active compound or compounds in a certain
part
of the intestinal tract in a delayed manner. Examples of embedding
compositions
which can be used are polymeric substances and waxes. The active compounds
can also be in microencapsulated form, if appropriate, with one or more of the
above-mentioned excipients.
Liquid dosage forms for oral administration include pharmaceutically
acceptable emulsions, solutions, suspensions, syrups, and elixirs. In addition
to the
active compounds, the liquid dosage forms may contain inert diluents commonly
used in the art, such as water or other solvents, solubilizing agents and
emulsifiers,
as for example, ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl
acetate,
benzyl alcohol, benzyl benzoate, propyleneglycol, 1,3-butyleneglycol,
dimethylformamide, oils, in particular, cottonseed oil, groundnut oil, corn
germ
oil, olive oil, castor oil, and sesame oil, glycerol, tetrahydrofurfuryl
alcohol,
polyethyleneglycols, and fatty acid esters of sorbitan or mixtures of these
substances, and the like.
Besides such inert diluents, the composition can also include adjuvants,
such as wetting agents, emulsifying and suspending agents, sweetening,
flavoring,
and perfuming agents.
Suspensions, in addition to the active compounds, may contain suspending
agents, as for example, ethoxylated isostearyl alcohols, polyoxyethylene
sorbitol
and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide,
bentonite, agar-agar, and tragacanth, or mixtures of these substances, and the
like.
Compositions for rectal administrations are preferably suppositories which
can be prepared by mixing the compounds of the present invention with suitable
nonirritating excipients or carriers such as cocoa butter, polyethyleneglycol
or a
suppository wax, which are solid at ordinary temperatures but liquid at body
CA 02357450 2001-09-19
-21-
temperature and therefore, melt in the rectum or vaginal cavity and release
the
active component.
Dosage forms for topical administration of a compound of this invention
include ointments, powders, sprays, and inhalants. The active component is
admixed under sterile conditions with a physiologically acceptable carrier and
any
preservatives, buffers, or propellants as may be required. Ophthalmic
formulations, eye ointments, powders, and solutions are also contemplated as
being within the scope of this invention.
In a preferred embodiment of the invention, the compound is labeled and
introduced into a patient in a detectable quantity and after suffcient time
has
passed for the compound to become associated with amyloid deposits, the
labeled
compound is detected noninvasively inside the patient. In another embodiment
of
the invention, a labeled compound of Formula I is introduced into a patient,
su~cient time is allowed for the compound to become associated with amyloid
deposits, and then a sample of tissue from the patient is removed and the
labeled
compound in the tissue is detected apart from the patient. In a third
embodiment
of the invention, a tissue sample is removed from a patient and a labeled
compound of Formula I is introduced into the tissue sample. After a su~cient
amount of time for the compound to become bound to amyloid deposits, the
compound is detected.
The administration of the labeled compound to a patient can be by a
general or local administration route. For example, the labeled compound may
be
administered to the patient such that it is delivered throughout the body.
Alternatively, the labeled compound can be administered to a specific organ or
tissue of interest. For example, it is desirable to locate and quantitate
amyloid
deposits in the brain in order to diagnose or track the progress of
Alzheimer's
disease in a patient.
The term "tissue" means a part of a patient's body. Examples of tissues
include the brain, heart, liver, blood vessels, and arteries. A detectable
quantity is
a quantity of labeled compound necessary to be detected by the detection
method
chosen. The amount of a labeled compound to be introduced into a patient in
order
to provide for detection can readily be determined by those skilled in the
art. For
example, increasing amounts of the labeled compound can be given to a patient
CA 02357450 2001-09-19
-22-
until the compound is detected by the detection method of choice. A label is
introduced into the compounds to provide for detection of the compounds.
The term "patient" means humans and other animals such as horses, dogs,
cats, and sheep. Those skilled in the art are also familiar with determining
the
amount of time sufficient for a compound to become associated with amyloid
deposits. The amount of time necessary can easily be determined by introducing
a
detectable amount of a labeled compound of Formula I into a patient and then
detecting the labeled compound at various times after administration.
The term "associated" means a chemical interaction between the labeled
compound and the amyloid deposit. Examples of associations include covalent
bonds, ionic bonds, hydrophilic-hydrophilic interactions, hydrophobic-
hydrophobic interactions, and complexes.
The present invention also provides a method of inhibiting the aggregation
of amyloid proteins to form amyloid deposits, by administering to a patient in
need of inhibition of the aggregation of amyloid protein an amyloid protein
inhibiting amount of a compound of Formula I. Those skilled in the art are
readily
able to determine an amyloid inhibiting amount by simply administering a
compound of Formula I to a patient in increasing amounts until the growth of
amyloid deposits is decreased or stopped. The rate of growth can be assessed
using imaging or by taking a tissue sample from a patient and observing the
amyloid deposits therein.
A patient in need of inhibition of the aggregation of amyloid proteins is a
patient having a disease or condition in which amyloid proteins aggregate.
Examples of such diseases and conditions include Mediterranean fever, Muckle-
Wells syndrome, idiopathetic myeloma, amyloid polyneuropathy, amyloid
cardiomyopathy, systemic senile amyloidosis, amyloid polyneuropathy,
hereditary
cerebral hemorrhage with amyloidosis, Alzheimer's disease, Downs syndrome,
sickle cell anemia, scrapie, Parkinson's disease, Creutzfeldt-Jakob disease,
kuru,
Gerstmann-Straussler-Scheinker syndrome, medullary carcinoma of the thyroid,
isolated atrial amyloid, (32-microglobulin amyloid in dialysis patients,
inclusion
body myositis, /32-amyloid deposits in muscle wasting disease, and Islets of
Langerhans diabetes type 2 insulinoma.
CA 02357450 2001-09-19
-23-
The compounds of the present invention can be administered to a patient at
dosage levels in the range of about 0.1 mg/day to about 1000 mg/day. For a
normal human adult having a body weight of about 70 kg, a dosage in the range
of
about 0.01 mg/kg to about 100 mg/kg of body weight per day is sufficient. The
specific dosage used, however, can vary. For example, the dosage can depend on
a
number of factors including the requirements of the patient, the severity of
the
condition being treated, and the pharmacological activity of the compound
being
used. The determination of optimum dosages for a particular patient is well-
known to those skilled in the art.
Armed with the disclosure provided herein (particularly the schemes and
the synthetic examples described above) and knowledge common to all who
practice in the field, those of ordinary skill in the art will be able to make
and use
the entire scope of compounds disclosed herein.
The invention is illustrated further by the following detailed examples
1 S which are not to be construed as limiting the invention in scope or spirit
to the
specific procedures described in them.
The starting materials and various intermediates may be obtained from
commercial sources, prepared from commercially available organic compounds,
or prepared using well-known synthetic methods.
Representative examples of methods for preparing intermediates of the
invention are set forth in the examples below.
EXAMPLE 1
Synthesis of 3-nitrobenzo[b]phenoxazinecarboxylic acid (Compound 21)
O N02
N
H
C02H
CA 02357450 2001-09-19
-24-
1. 2-[(3-Hydrozy(2-naphthyl))amino]-3,5-dinitrobenzoic acid
N02
N02
A mixture of 3-aminonaphthalen-2-of (4.65 g, 0.029 mol), 2-chloro-
3,5-dinitrobenzoic acid (7.20 g, 0.029 mol), water (30 mL), and 2N sodium
acetate (NaOAc) (15 mL) is stirred and heated under reflux for 15 minutes. To
the
resulting thick paste is added 2N sodium hydroxide (NaOH) ( 15 mL), and the
mixture is stirred and heated for another 15 minutes. The dark purple sodium
salt
is washed with cold brine. An aqueous solution of the filtrate is acidified
with
dilute HCl and the free acid precipitates as a dark colored solid. The
precipitate is
triturated in boiling 10% MeOH/H20, filtered, rinsed with cold 10% MeOHlH20,
and dried at room temperature in a vacuum oven overnight to yield an orange
solid (9.00 g, 0.024 mol, 84%) as the desired product; mp 154-156°C.
Analysis for C17H11N30T0.75 H20:
Calcd: C 53.34; H 3.29; N 10.98.
Found: C 53.00; H 2.94; N 10.58.
2. 3-Nitrobenzo[b]phenozazinecarbozylic acid
A mixture of 2-[(3-hydroxyl2-naphthyl))amino]-3,5-dinitrobenzoic acid
(8.50 g, 0.023 mmol), water (30 mL), and 2N sodium hydroxide (20 mL) is
stirred
and heated under reflux overnight. The resulting dark purple sodium salt is
washed with cold brine and filtered. An aqueous solution of the salt is
acidified
with dilute HCl and the free acid precipitates as a dark colored solid. The
filtrate is
acidified with dilute HCl and the free acid precipitates as a dark colored
solid. The
precipitate is triturated in boiling 10% MeOH/Fi20, filtered, rinsed with cold
10%
MeOH/H20, and dried at room temperature in a vacuum oven overnight to yield a
brown solid (0.68 g, 0.002 mol, 7%) as the desired product (compound 21);
CA 02357450 2001-09-19
-25-
mp >230°C.
Analysis for C17H1pN205~0.29 H20:
Calcd: C 62.35, H 3.26, N 8.55.
Found: C 61.96, H 2.95, N 8.96.
EXAMPLE 2
Synthesis of 3-nitro-8-phenylphenoxazinecarboxylic acid (Compound 2)
1. 2-[(2-Hydrozy-5-phenylphenyl)amino]-3,5-dinitrobenzoic acid
N02
N02
The title compound is prepared from 2-amino-4-phenylphenol (5.59 g,
0.03 mol), 2-chloro-3,5-dinitrobenzoic acid (7.45 g, 0.03 mol), water (30 mL),
2N NaOAc (15 mL), and 2N NaOH (15 mL) using the procedure of Example 1,
Step 1 as a red solid (9.37 g, 0.023 mol, 78%); mp 215-217°C.
Analysis for C19H13N307'1.13 H20:
Calcd: C 54.90; H 3.70, N 10.11.
Found: C 54.51, H 3.57, N 9.84.
2. 3-Nitro-8-phenylphenogazinecarbozylic acid
2-[(2-Hydroxy-5-phenylphenyl)amino]-3,5-dinitrobenzoic acid (8.82 g,
0.022 mmol), water (50 mL), and lON NaOH (10 mL) are stirred and heated
under reflux overnight. The reaction is worked up as in Example 1, Step 2, to
af~'ord the final product (compound 2) as a brown solid (5.75 g, 0.017 mol,
75%);
mp >250°C.
Analysis for C19H12N205'0.10 H20:
Calcd: C 65.18; H 3.51, N 8.00.
Found: C 64.79, H 3.30, N 8.18.
CA 02357450 2001-09-19
-26
EXAMPLE 3
Synthesis of 7-[2-(3,4-dichlorophenyl)ethyl]-3-nitrophenoxazinecarboxylic acid
(Compound 5)
1. Bromo[(3,4-dichlorophenyl)methyl]triphenylphosphorane
C1
C1 ~ P(Ph)3Br
A mixture of 4-bromomethyl-1,2-dichlorobenzene (2.40 g, 0.01 mol), end
triphenylphosphine (5.24 g, 0.02 mol) in toluene (30 mL) is stirred for 16
hours at
room temperature. The solid is filtered, rinsed with toluene, and oven dried
to
yield a white powder (3.95 g, 0.0078 mol, 78%) as the desired product. 1H NMR
(8 ppm): 7.89-7.61 (m, 15H), 7.50 (d, J=2.3 Hz, 1H), 6.97 (dt, J=8.3 Hz, 2.3
Hz,
1H), 5.20 (d, J=15.9 Hz, 2H).
2. 5-[2-(3,4-Dichlorophenyl)vinyl]-2-nitrophenol
C1
C1 I ~ ~ ~ OH
(/
N02
A solution of bromo[(3,4-dichlorophenyl)methyl]triphenylphosphorane
(11.54 g, 22.98 mmol) in dry THF (250 mL) is cooled to -78°C. Sodium
hexamethyldisilazane (NaHDMS) (1.0 M/THF, 50.33 mL, 50.33 mol) is added
dropwise to maintain the temperature at -78°C. After stirring for 20
minutes, a
solution of 3-hydroxy-4-nitrobenzaldehyde (4.22 g, 25.28 mmol) in THF (50 mL)
is added dropwise. The resulting mixture is allowed to warm to room
temperature
within 3 hours. The mixture is then quenched with saturated ammonium chloride
(NH4Cl) and extracted with ethyl acetate (EtOAc). The organic layers are then
washed with O.1N HCl solution, H20, and brine, respectively. The solution is
dried over sodium sulfate (Na2S04) and concentrated in vacuo to give a light
brown oil. Purification by flash chromatography (silica gel, 15% EtOAc/hexane)
yields 4.29 g (13.8 mmol, 60%) of the desired product; mp 105-106°C.
CA 02357450 2001-09-19
-27-
Analysis for C14H9N103C12~0.08 EtOAc:
Calcd: C 54.23; H 3.06; N 4.42.
Found: C 54.33; H 3.04; N 4.02.
3. 2-Amino-5-[2-(3,4-dichlorophenyl)ethyl]phenol
C1
C1 I ~ ~ off
~2
A sample of 5-[2-(3,4-dichlorophenyl)vinyl]-2-nitrophenol (4.17 g,
13.45 mmol) in THF (100 mL) is reduced in the presence of Raney Nickel (1 g)
at
22°C to 29°C (0P = 4.3 psi). The reaction mixture is filtered,
and the filtrate is
concentrated in vacuo to give a brown solid, 3.5 g (12.4 mmol, 92%) of the
desired product; mp 147-149°C.
Analysis for C1,4H13N101C12~
Calcd: C 59.59; H 4.64; N 4.96.
Found: C 59.68; H 4.60; N 4.71.
4. 7-[2-(3,4-Dichlorophenyl)ethyl]-3-nitrophenogazinecarboaylic acid
A mixture of 2-amino-5-[2-(3,4-dichlorophenyl)ethyl]phenol (0.73 g,
2.59 mmol), 2-chloro-3,5-dinitrobenzoic acid (0.68 g, 2.59 mmol), water (3
mL),
and 2N sodium acetate ( 1.3 mL) is stirred and heated under reflux for 5
hours. To
the resulting thick paste is added 2N sodium hydroxide (15 mL) and the mixture
is
stirred and heated for another 3 hours. The reaction mixture is acidified with
dilute
HCl and the free acid forms as a dark precipitate. The precipitate is filtered
o~ and
washed with H20. Purification by flash chromatography (silica gel,
toluene:EtOAc:AcOH [30:5:1]) yields 0.21 g (0.47 mmol, 18%) of the desired
product (compound 5); mp >250°C.
Analysis for C21H14N205C12'0.3 toluene~0.25 H20:
Calcd: C 58.12; H 3.57; N, 5.87.
Found: C 57.77; H 3.29; N 5.52.
CA 02357450 2001-09-19
-28-
EXAMPLE 4
Synthesis of 7-[3-(3,4-Dichlorophenyl)-3-oxoprop-1-enyl]-
3-nitrophenoxazinecarboxylic acid (Compound 6)
1. 1-(3,4-Dichlorophenyl)-3-hydrozy-3-(3-hydrogy-4-nitrophenyl)-
propan-1-one
O OH
Cl I ~ I ~ OH
C1
~2
Sodium hydroxide (4.88 g, 0. I22 mmol) is dissolved in water (80 mL) and
95% EtOH (80 mL) and cooled to 0°C with an ice-H20 bath.
1-(3,4-Dichlorophenyl)ethanone (23.10 g, 0.122 mol) is added in one portion.
After the addition, the mixture is warmed to 15°C. 3-hydroxy-
4-nitrobenzaldehyde (20.42 g, 0.122 mol) is then added with rigorous stirring.
After stirring for 5 minutes, the reaction mixture is diluted with 95% EtOH
(300 mL). The resulting tan mixture is stirred at room temperature overnight.
The
reaction mixture is acidified with 3N HCl and stirred for 30 minutes. The
resulting
yellow solid is filtered off, washed with H20, washed with 5% MeOH/CH2C12,
and oven dried (40°C) to yield a yellow solid (25.00 g, 0.074 mol, 61%)
of the
title compound; mp 163-166°C.
Analysis for C I SH9C 12N05
Calcd: C 50.59; H 3.11; N 3.93.
Found: C 50.61; H 2.81; N 3.81.
2. 2-Amino-5-[3-(3,4-dichlorophenyl)-3-hydrozypropyl)phenol
HO
C1 I ~ I ~ OH
Cl
~2
The title compound is prepared from 1-(3,4-dichlorophenyl)-3-hydroxy-
3-(3-hydroxy-4-nitrophenyl)propan-1-one (6.5 g, 18.25 mmol) in the presence of
CA 02357450 2001-09-19
-29-
Raney Nickel (4.0 g) in THF (100 mL) at 25°C (0P = 6.3 psi) using the
procedure
described in Example 5, Step 3. The reaction mixture is concentrated in vacuo
and
dried in an oven vacuum (30°C) to give a brown solid (5.9 g, 18.08
mmol, 99%)
of the desired product. MS: 326.0 (M~). 1H NMR (b ppm): 9.87 (s, 1H),
8.08 (d, J=2 Hz, 1H), 7.87 (dd, J=8.3 Hz, 1.7 Hz, 1H), 7.76 (d, J=8.3 Hz, 1H),
6.67 (s, 1H), 6.53 (d, J=8.1 Hz, 1H), 6.48 (d, J=8.0 Hz, 1H), 5.08 (d, J=4.2
Hz,
1H), 4.82 (ddd, J=4.2, 4.2, 8.4 Hz, 1H), 4.38 (s, 2H), 3.32 (dd, J=8.8, 16.6
Hz,
1H), 3.02 (dd, J=4.4, 15.4 Hz, 1H). -
3. 7-[3-(3,4-Dichlorophenyl)-3-ozoprop-1-enylJ-
3-nitrophenozazinecarbozylic acid
The title compound is prepared from 2-amino-5-[3-(3,4-dichlorophenyl)-
3-hydroxypropyl]phenol (2.00 g, 6.13 mmol), 2-chloro-3,5-dinitrobenzoic acid
(1.51 g, 6.13 mmol), water (5 mL), 2N sodium acetate (3 mL), and 2N sodium
hydroxide (3 mL) using the procedure described in Example 5, Step 4. This
procedure yields a dark solid (0.5 g, 1.06 mmol, 17%) as the desired product
(compound 6); mp >200°C.
Analysis for C22H12N206C12'0'05 H20:
Calcd: C 55.96; H 2.58; N 5.93.
Found: C 55.57; H 2.85; N 6.07.
EXAMPLE 5
Synthesis of 7-[3-(3,4-Dichlorophenyl)propyl]-3-nitrophenoxazine carboxylic
acid (Compound 7)
1. 5-[3-(3,4-Dichlorophenyl)-3-hydrogyprop-1-enylJ-2-nitrophenol
HO
C1 I ~ / I ~ OH
C1
N02
A solution of 1-(3,4-dichlorophenyl)-3-hydroxy-3-(3-hydroxy-
4-nitrophenyl)propan-1-one (15.0 g, 42.12 mmol), 15% ofNaOH (100 mL), and
EtOH (200 mL) is heated to reflux for 30 minutes and then cooled to room
CA 02357450 2001-09-19
-3 0-
temperature and allowed to stir overnight. The reaction mixture is acidified
with
10% H2S04 and stirred for 30 minutes. The precipitate is filtered off, washed
with H20, then 95% EtOH, and oven dried (40°C) to yield a red solid
(13.7 g,
40.51 mmol, 96%) of the title compound; mp 178-180°C.
Analysis for C15H9C12N04~0.4 H20:
Calcd: C 52.17; H 2.86; N 4.06.
Found: C 51.78; H 2.62; N 3.68.
2. 5-(3-(3, 4-Dichlorophenyl)propyl]-2-nitrophenol and 5-[3-(3, 4-
dichlorophenyl)-3-hydrozypropyl]-2-nitrophenol
HO
C1 I ~ I ~ OH Cl I ~ I ~ OH
i ~ i
Cl N02 Cl N02
A solution of 5-[3-(3,4-dichlorophenyl)-3-hydroxyprop-1-enyl]-
2-nitrophenol (5.97 g, 17.65 mmol), Et3 SiH (8.2 g, 70.62 mmol) in TFA (70 mL)
is stirred at room temperature for 10 days. The reaction mixture is
concentrated to
dryness, and the resulting residue is dissolved in H20 (100 mL) and extracted
1 S with EtOAc. The organic layer is dried (MgS04) and concentrated to give a
brown oil. Purification by flash chromatography (silica gel, 1% MeOH/CH2C12)
affords 3.8 g (11.65 mmol, 66%) ofthe desired product:
5-[3-(3,4-dichlorophenyl)propyl]-2-nitrophenol. MS: 321.9 (M+) and 2.0 g
(5.8 mmol, 33%) of 5-[3-(3,4-dichlorophenyl)-3-hydroxypropyl]-2-nitrophenol;
mp 90-93°C.
Analysis for C15H15N104C12:
Calcd: C 58.34; H 4.39; N 4.07.
Found: C 52.38; H 3.97; N 3.91.
CA 02357450 2001-09-19
-31-
3. 2-Amino-5-[3-(3, 4-dichlorophenyl)propyl]phenol
Cl I ~ I ~ OH
C1
~2
The title compound is prepared from 5-[3-(3, 4-dichlorophenyl)propyl]-
2-nitrophenol (7.0 g, 21.46 mmol) and Raney Nickel (3.0 g) in THF (100 mL) at
24°C to 28°C (OP = 38.1 psi) using the procedure described in
Example 5, Step 3.
Purification by flash chromatography (silica gel, 20%, 50%, 80% EtOAc/Hexane)
affords a white solid (1.16 g, 3.92 mmol, 18%) of the desired product;
mp 79-82°C.
HRMS analysis for C15H15N101C12~
Calcd: 296.0609.
Found: 296.0621 (~ = 4.05 ppm).
4. 7-[3-(3,4-Dichlorophenyl)propyl]-3-nitrophenozazine carboxylic acid
The title compound is prepared from 2-amino-5-[3-(3,4-
dichlorophenyl)propyl]phenol (1.11 g, 3.75 mmol), 2-chloro-3,5-dinitrobenzoic
1 S acid (0.93 g, 3.75 mmol), water (3 mL), 2N sodium acetate (2 mL), and 2N
sodium hydroxide (2 mL) using the procedure described in Example 5, Step 4.
This procedure yields a dark solid (1.50 g, 3.27 mmol, 87%) as the desired
product (compound 7); mp 215-217°C.
Analysis for C22H16N205C12'0.45 H20~0.05 C7H3N206C1 (2-chloro-
3,5-dinitrobenzoic acid):
Calcd: C 55.96; H 3.58; N 6.13.
Found: C 55.60; H 3.20; N 5.88.
EXAMPLE 6
Synthesis of 7-[3-(3, 4-Dichlorophenyl)-3-hydroxypropyl]-3-nitrophenoxazine
carboxylic acid (Compound 8)
CA 02357450 2001-09-19
-3 2-
1. 2-Amino-5-[3-(3,4-dichlorophenyl)-3-hydrozypropyl]phenol
HO
C1 ( ~ I ~ OH
C1
~2
The title compound is prepared from 5-[3-(3,4-dichlorophenyl)-
3-hydroxypropyl]-2-nitrophenol (2.0 g, 5.86 mmol) is Raney Nickel (0.5 g) in
THF (50 mL) at 24°C to 25°C (0P = 38.3 psi) using the
procedure described in
Example 5, Step 3. This procedure yields an orange solid (1.43 g, 4.58 mmol,
79%) of the desired product; mp 121-123°C.
Analysis for C15H15N102C12~
Calcd: C 57.71; H 4,84; N 4.49.
Found: C 57.40; H 4.71; N 4.35.
2. 7-[3-(3,4-Dichlorophenyl)-3-hydrozypropyl]-3-nitrophenoaazine
carboxylic acid
The title compound is prepared from 2-amino-5-[3,4-dichlorophenyl)-
3-hydroxypropyl]phenol (2.39 g, 7.66 mmol), 2-chloro-3,5-dinitrobenzoic acid
(1.89 g, 7.66 mmol), water (6 mL), 2N sodium acetate (4 mL), and 2N sodium
hydroxide (4 mL) using the procedure described in Example 5, Step 4. This
procedure affords a dark solid (3.40 g, 7.15 mmol, 93%) as the desired product
(compound 8); mp 218-220°C.
Analysis for C22H16N206C12'0.75 H20~0.05 C7H3N206C1 (2-Chloro-
3,5-dinitro-benzoic acid):
Calcd: C 53.57; H 3.55; N 5.87.
Found: C 53.20; H 3.25; N 5.85.
EXAMPLE 7
Synthesis of 3-Amino-7-[3-(3,4-dichlorophenyl)propyl]phenoxazine carboxylic
acid (Compound 9)
The title compound is prepared from 7-[3-(3,4-dichlorophenyl)propyl]-
3-nitrophenoxazinecarboxylic acid (compound 8) (0.86 g, 1.87 mmol) and Raney
CA 02357450 2001-09-19
-33-
Nickel (0.2 g) in THF (50 mL) at 24°C to 26°C (0P = 13.3
psi) using the
procedure described in Example 5, Step 3. This procedure yields a dark solid
(0.13 g, 0.3 mmol, 16%) of the desired product (compound 9); mp 213-
216°C.
Analysis for C22H18N203C12~0.55 H20:
Calcd: C 60.16; H 4.38; N 6.38.
Found: C 59.77; H 4.20; N 6.03.
EXAMPLE 8 _
The following compounds are prepared essentially according to the
procedures described in Examples 1-7 and shown in Schemes 1-4:
(a) Phenoxazinecarboxylic acid (compound 1);
(b) 3-Nitrophenoxazinecarboxylic acid (compound 3);
(c) 3-(Phenylmethoxy)phenoxazinecarboxylic acid (compound 4);
(d) 9-Chloro-8-(trifluoromethyl)benzo[b]phenoxazinecarboxylic acid
(compound 10);
(e) Benzo[b]phenoxazinecarboxylic acid (compound
11);
(f) 8,9-Dimethylbenzo[b]phenoxazinecarboxylic acid
(compound 12);
(g) 8,9-Dihydroxybenzo[b]phenoxazinecarboxylic acid
(compound 13);
(h) 8,9-Dichlorobenzo[b]phenoxazinecarboxylic acid
(compound 14);
(i) 7-Phenylphenoxazinecarboxylic acid (compound
15);
(j) 7-(3,4-Dichlorophenyl)phenoxazinecarboxylic acid
(compound 16);
(k) 7-Benzylphenoxazinecarboxylic acid (compound
17);
(1) 7-((3,4-Dichlorophenyl)methyl]phenoxazinecarboxylic
acid
(compound 18);
(m) 7-[2-(3,4-Dichlorophenyl)ethyl]phenoxazinecarboxylic acid
(compound 19); and
(n) 8-(3,4-Dichlorophenyl)phenoxazinecarboxylic acid (compound 20).
As noted above, the compounds of Formula I are useful because of their
ability to inhibit amyloid protein aggregation. The inhibitory activity of the
invention compounds has been determined in several biological assays routinely
utilized by those skilled in the art to measure such amyloid inhibition.
CA 02357450 2001-09-19
-34-
Representative invention compounds have been evaluated in the following
amyloid assays.
1. BASSR (Beta-Amyloid Self Seeding Radioassay)
An assay for inhibitors of self seeded amyloid fibril growth
Materials:
Stock Solutions:
Assay Buffer- 50 mM sodium phosphate, pH 7.5, 100 mM NaCI,
0.02% NaN3, 1 M urea (filter and store at 4°C)
Soluble A,Q (I-40) peptide (Bachem, Torrance, CA) -2.2 mg/mL in
deionized H20 (is stored in aliquots at -20°C; is kept on ice when
thawed) will self seed after 1 week storage. Typically, the solution
is stored until no lag phase is seen in the assay.
1251 labeledA,~3(I-40)-150K to 350K cpm/pL in 100% acetonitrile -
0.1% trifluoroacetic acid (TFA)-1% (3-mercaptoethanol (aliquots
stored at -20°C). 125I_labeled A~3(1-40) is made in accordance
with the procedure set forth by LeVine H., III, in Neurobiol. Aging,
1995;16:755, which is hereby incorporated by reference, or this
reagent may be purchased from Amersham, Arlington Heights,
Illinois.
Final assay conditions: 30 1tM soluble A/.j (1-40) in deionized water in
assay buffer + 20K to 50K cpm 125I_labeled A~3 (1-40) per assay.
Compound to be tested is dissolved in dimethylsulfoxide (DMSO),
typically 5 to 50 mM stock, such that the final concentration of
DMSO is <1% v/v in the assay.
Assay: Reaction mixture for 50 assays (on ice) is comprised of 0.1 to
0.2 u.L, of 125I_labeled A1251-labeled A,Q ( 1-40) + 1 p,L of soluble
A~3(1-40) + 13.5 ~I, assay buffer per assay. The following are the
amounts of the components of the reaction mixture sufficient for
50 assay wells.
5-10 N.L 125I_labeled A~3 (1-40) dried down
675 p.I, assay buffer
CA 02357450 2001-09-19
-3 5-
50 pL, soluble A~3 (1-40)
Assay Method:
1) The reaction mixture of above is prepared by mixing components
and storing on ice.
2) 14.5 N,I, of the reaction mixture is pipetted into each of 50 wells on
a polypropylene U-bottom 96-well microtiter plate on ice
(Costar 3794).
3) 1.7 N.L, of diluted compound to be tested is added to each well in a
column of eight, including solvent control. Serial 3-fold dilutions
from 1 mM (100 pM final) in assay buffer - urea = 7 dilutions +
zero. Each 96-well plate can therefore accommodate 11 samples +
1 Congo Red control (0.039-5 pM final in 2-fold steps).
4) The plate with aluminum film (Beckman 538619) is sealed and
incubated for 10 minutes on ice.
5) The temperature is raised to 37°C and incubated for 3 to 5 hours
(depending on the lot of the peptide).
6) The aluminum film is removed and 200 p,L/well of ice cold assay
buffer with urea is added. The radiolabeled fibrils are collected by
vacuum filtration through 0.2 p.m pore size GVWP filters in
96-well plates (Millipore MAGV N22, Bedford, MA). The
radioactivity of the filters is determined by using standard methods
well-known to those skilled in the art.
2. BASST (Beta-Amyloid Self seeding, ThioflavinT)
An assay for inhibitors of self seeded amyloid fibril growth
Materials:
Stock Solutions:
Assay Buffer-50 mM sodium phosphate, pH 7.5, 100 mM NaCI,
0.02% NaN3, 1 M urea (filter and store at 4°C)
Soluble A,Q (I-40)-2.2 mg/mL in deionized H20 (is stored in aliquots at
-20°C; is kept on ice when thawed) will self seed after 1 week
CA 02357450 2001-09-19
-36-
storage. Typically, the solution is stored until no lag phase is seen
in the assay.
Final assay conditions: 30 l.iM soluble A,Q (1-40) in deionized water in
assay buffer. Compound to be tested is dissolved in DMSO,
typically 5 to 50 mM stock, such that the final concentration of
DMSO is <1% v/v in the assay.
Assay: Reaction mixture for 50 assays (on ice) is comprised of 1 NT. of
soluble A,(3 (1-40) + 13.5 p.L, assay buffer per assay. The follovuing
are the amounts of the components of the reaction mixture that
result in each of the 50 assay wells.
50 p,L soluble A~3 (1-40)
675 p.L, assay buffer
Assay Method:
1) The reaction mix above is prepared by mixing the components and
storing on ice.
2) 14.5 p,I. of reaction mixture is pipetted into each of 50 wells of a
polystyrene U-bottom, 96-well microtiter plate (Corning 25881-96)
on ice.
3) 1.7 N.L, of diluted compound to be tested is added to each well in a
column of eight, including solvent control. Serial 3-fold dilutions
from 1 mM (100 pM final) in assay buffer - urea = 7 dilutions +
zero. Each 96-well plate can therefore accommodate 11 samples +
1 Congo Red control (0.039-5 ~M final in 2-fold steps).
4) The plate with aluminum film is sealed and incubated for
10 minutes on ice.
5) The temperature is raised to 37°C and incubated for 3 to 5 hours
(depending on the lot of the peptide).
6) The aluminum film is removed and 250 p,L/well of 5 p,M
thioflavin T (ThT) [T-3516, Sigma-Aldrich] is added in 50 mM
glycine-NaOH, pH 8.5. Fluorescence is read on a plate reader
(ex = 440 nm/20 nm ; em = 485 nm/20 nm) within 5 minutes.
CA 02357450 2001-09-19
-37-
3. BAPA (Beta-Amyloid Peptide Aggregation)
This assay is used to provide a measure of inhibition by a compound
against the aggregation behavior of the beta amyloid peptide.
The purpose of this assay is to provide a higher volume method of
assaying the amount of beta amyloid aggregation using an endpoint assay based
on filtration. In this assay, hexafluoroisopropanol (I-~'IP) is used to break
down
the initial amyloid peptide to a monomer state and a concentration of 33 N.M
is
used, a concentration which is high enough so that aggregation will occur at
pH 6.0 in several hours.
Method:
(3-Amyloid Peptide Aggregation, pH 6.0 (BAPA)
To a 96-well plate (Costar 3794) is added 25 N,L 50 mM Phosphate Buffer
(pH 6.0), 10 p,I, 0.5 mg/mL A(3 (1-40) peptide in 20% HFIP +
0.1 p,L/assay radioiodinated 1251 A(3 (1-40) (1251 A(3(1-40)], and
1 p.L, of the compound to be tested, starting at 50 mM with a
concentration ofDMSO <1%. The reaction is incubated for 2 to
4 hours at room temperature. The reaction is stopped with 200 p.L,
of 50 mM phosphate buffer, pH 6.0, and filtered through a 0.2 p,m
96-well filter plate (Millipore MAGU N22). The filter plate is
washed with 100 p.L, of the same phosphate buffer. Aggregation is
detected on a Microbeta counter after impregnating the filters with
Meltilex (1450-441) and is corrected for background.
4. BATYM ASSAY
Methods:
Required A(3 (1-42) (California Peptide) is dried from its
hexafluoroisopropanol (I~IP) stock solution. The A(3 (1-42) is dissolved in
DMSO and then mixed with phosphate buffered saline (PBS) (pH 7.4). The mixed
A(3 (1-42) solution is filtered with a GVWP 0.22 ~tm syringe filter
(Millipore,
Bedford, MA). The compound to be tested in DMSO (50 times concentrate) is put
into each well (0.5 ~L/well) of a 96-well plate. The A(3 (1-42) solution is
added
CA 02357450 2001-09-19
-3 8-
into each well (25 pI,/well). The plate is centrifuged at 1000 g for 5 minutes
and
incubated at 37°C for 1 day (A(3 1-42; final concentration 100 ~.
After incubation Thioflavin T (ThT) (30 ~ solution in glycine-NaOH
buffer (pH 8.5, 50 mIvn is added into each well (250 pi./well), fluorescence
is
measured (ex = 440/20 nm, em = 485/20 nm) using a fluorescence plate reader.
The inhibitory activity is calculated as the reduction of fluorescence with
the
following formula:
Inhibition (%) ={(F(A(3)-F(A(3 + compound))/{F(A(3)- -
F(solvent - compound)} x 100.
The ICSps are calculated by a curve-fitting program using the equation
given below. The data is obtained from two different experiments in
triplicate.
F(x) = loo-loo/ {1+(IC50 /lpx)n};
x = concentration of tested compound (M),
IC50 = ~~
n = Hill coe~cient.
The results of these assays for compounds of the present invention are
shown in Table 2.
CA 02357450 2001-09-19
-39
TABLE 2
ExampleCompound BASSR BASST BATYM BAPA
No. No. (IC50 = (IC50 = (IC50 = (IC50
~ N~ I~ - N~
1 21 12, 11, 1 6.7 67
10
2 2 100, 60, 1 4.15 5
70,
60
3 5 60, 3, 1 7.89 (P) 0.9 (Q)
> 100 (ppt) 3 .02 (Q) -
4 6 21, 22, 1 4.61 >100
25
7 30 (ppt), 0.5 1.88 >100
20,
6
6 8 > 100, 0.6 4.18 100
100,
100
7 9 60, > 100 3 8.75 86
8b 3 8 13, 40, 62, >100
23,
23, 40, (BAPA2)
13
8c 4 14 8.4, 45, 50, >50
45,
8.44 (BAPA2)
ppt = Precipitate and indicates that a precipitate formed at the indicated
concentration
The above data establishes that representative invention compounds are
active in standard assays used to measure inhibition of protein aggregation.
The
compounds exhibit excellent specificity, for example, as shown in the BASST
assay, as well as the BATYM assay. The compounds are thus useful to clinically
5 inhibit amyloid protein aggregation and to image amyloid deposits for
diagnostic
use. The compounds will be used in the form of pharmaceutical formulations,
and
the following examples illustrate typical compositions.
CA 02357450 2001-09-19
-40-
EXAMPLE 9
Tablet Formulation
Ingredient Amount
Compound of Example 1 50 mg
Lactose 80 mg
Cornstarch (for mix) 10 mg
Cornstarch (for paste) 8 mg
Magnesium Stearate (1%) 2 mg
150 mg
The compound of Example 1 (Compound 21) is mixed with the lactose
and cornstarch (for mix) and blended to uniformity to a powder. The cornstarch
(for paste) is suspended in 6 mL of water and heated with stirring to form a
paste.
The paste is added to the mixed powder, and the mixture is granulated. The wet
granules are passed through a No. 8 hard screen and dried at 50°C. The
mixture is
lubricated with 1% magnesium stearate and compressed into a tablet. The
tablets
are administered to a patient at the rate of 1 to 4 each day for prevention of
amyloid protein aggregation and treatment of Alzheimer's disease.
EXAMPLE 10
Parenteral Solution
In a solution of 700 mL of propylene glycol and 200 mL of water for
injection is added 20.0 g of Compound No. 7 (Example 5). The mixture is
stirred
and the pH is adjusted to 5.5 with hydrochloric acid. The volume is adjusted
to
1000 mL with water for injection. The solution is sterilized, filled into 5.0
mL
ampoules, each containing 2.0 mL (40 mg of Compound No. 7), and sealed under
nitrogen. The solution is administered by injection to a patient suffering
from
medullary carcinoma of the thyroid and in need of treatment.
CA 02357450 2001-09-19
-41-
EXAMPLE 11
Patch Formulation
Ten milligrams of Compound No. 13 (Example 8g) is mixed with 1 mL of
propylene glycol and 2 mg of acrylic-based polymer adhesive containing a
resinous cross-linking agent. The mixture is applied to an impermeable backing
(30 cm2) and applied to the upper back of a patient for sustained release
treatment
of amyloid polyneuropathy.
The invention and the manner and process of making and using it are now
described in such full, clear, concise, and exact terms as to enable any
person
skilled in the art to which it pertains, to make and use the same. It is to be
understood that the foregoing describes preferred embodiments of the present
invention and that modifications may be made therein without departing from
the
spirit or scope of the present invention as set forth in the claims. To
particularly
point out and distinctly claim the subject matter regarded as invention, the
following claims conclude this specification. ,
